

Peripheral blood neutrophil cytokine hyper-reactivity in chronic periodontitis

Ling, Martin R; Chapple, Iain Lc; Matthews, John B

DOI:

[10.1177/1753425915589387](https://doi.org/10.1177/1753425915589387)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Ling, MR, Chapple, IL & Matthews, JB 2015, 'Peripheral blood neutrophil cytokine hyper-reactivity in chronic periodontitis', *Innate immunity*, vol. 21, no. 7, DOI: 10.1177/1753425915589387, pp. 714–725.
<https://doi.org/10.1177/1753425915589387>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Peripheral blood neutrophil cytokine hyper-reactivity in chronic periodontitis

Martin R. Ling*
Iain L.C.Chapple
John B. Matthews

Periodontal Research Group and MRC Centre for Immune Regulation, College of Medical and Dental Sciences, The University of Birmingham, St Chad's Queensway, Birmingham B4 6NN, United Kingdom.

Running title: Neutrophil cytokine release in chronic periodontitis.

*Corresponding author:

Address: School of Dentistry,
College of Medical and Dental Sciences,
The University of Birmingham,
St Chad's Queensway,
Birmingham B4 6NN,
United Kingdom.

Tel: +44 (0)121 466 5128

Fax: +44 (0)121 466 5461

Email: M.R.Ling@bham.ac.uk

ABSTRACT

Pro-inflammatory cytokine release (IL-8, IL-6, TNF α , IL-1 β) by peripheral blood neutrophils (PBN), isolated from periodontitis patients (before/after therapy) and matched controls, was determined after 18h culture in the presence/absence of *Escherichia coli* LPS, opsonised *Staphylococcus aureus*, heat-killed *Fusobacterium nucleatum* and *Porphyromonas gingivalis*. All cultures demonstrated differences in the amounts of each cytokine detected ($P<0.0001$), with a clear release pattern (IL-8>IL-6>TNF α =IL-1 β). Median cytokine release from unstimulated patient neutrophils was consistently, but non-significantly, higher than from control cells. Stimulated cytokine release from untreated patient neutrophils was also consistently higher than control cells. This hyper-reactivity was significant for all tested cytokines when data for all stimuli were combined ($P<0.016$). In terms of individual stimuli, significant hyper-reactivity was detected with LPS (IL-8; $P<0.04$), *F. nucleatum* (IL-8, TNF α ; $P<0.05$), opsonised *S. aureus* (IL-8, TNF α , IL-1 β ; $P<0.05$) and *P. gingivalis* (IL-8, IL-1 β ; $P<0.032$). Cytokine production by patient neutrophils did not reduce following successful non-surgical periodontal therapy and, except for responses to *F. nucleatum*, the cytokine hyper-reactivity detected pre-therapy was retained. These data demonstrate that chronic periodontitis is characterised by neutrophils that constitutively exhibit cytokine hyper-reactivity, the effects of which could modulate local and systemic inflammatory-immune responses and influence the risk and severity of periodontitis-associated systemic inflammatory diseases.

Key words: Cytokine; interleukin; neutrophil; periodontitis; TNF α .

INTRODUCTION

Chronic periodontitis is one of the most prevalent chronic inflammatory diseases of humans and in its most severe form is the sixth most prevalent disease of man, affecting 11.2% of the global population and representing a substantial public health burden.¹ The pathogenesis of chronic periodontitis is associated with a dysregulated host inflammatory-immune response to intra-oral plaque bacteria,² which is responsible for the majority of periodontal tissue damage.³ A hyper-inflammatory neutrophil phenotype is considered central to the pathogenesis of chronic periodontitis⁴ and also many of the systemic inflammatory diseases associated with periodontitis including type-2 diabetes⁵ and cardiovascular disease.⁶ As such, neutrophilic “hyper-inflammation” may represent one causal mechanism by which periodontitis contributes to co-morbidity.

Coordination of inflammatory-immune responses including neutrophil function involves the release of locally-produced and systemically circulating cytokines.⁷ Originally, monocytes and lymphocytes were regarded as the predominant source of pro-inflammatory cytokines in inflammatory lesions with neutrophils thought to produce only IL-8.⁸ However, neutrophils themselves have been shown to release physiologically-relevant concentrations of various cytokines including IL-8, IL-6, TNF α and IL-1 β ⁹⁻¹¹ and therefore play an active role in co-ordinating the inflammatory-immune response, in addition to their traditional antimicrobial activity.¹² Given the large numbers of neutrophils in peripheral blood and that they represent the dominant inflammatory cell in the periodontal tissues during periodontitis, neutrophil cytokine release is likely to significantly impact on the host response locally and systemically, with the latter increasing the risk of co-morbidity.

There have been few studies of neutrophil-derived cytokines in the pathogenesis of periodontitis and related systemic disease, despite their potential importance. The majority of studies investigating cytokines in chronic periodontitis have been performed on plasma, GCF and tissue biopsy samples, and have generally shown higher levels in disease. To date, there have been only three published studies investigating peripheral blood neutrophil cytokine release in patients with chronic periodontitis.¹³⁻¹⁵ Two studies demonstrated no significant difference in neutrophil IL-8, IL-1 β and TNF- α release in chronic periodontitis compared to healthy controls in the absence or presence of GM-CSF

or opsonised *S. aureus*.^{13, 14} By contrast, the third study reported significantly reduced neutrophil IL-8 release from patient neutrophils compared to control cells in the presence and absence of LPS, phytohemagglutinin (PHA), zymosan A, *P. gingivalis* or *A. actinomycetemcomitans*.¹⁵ All these studies used short culture times to determine cytokine production (≤ 5 hr), which may have been too short to accurately determine neutrophil cytokine production. Although the specific mechanisms involved in neutrophil cytokine release are incompletely defined,¹⁶ neutrophils are not known to store cytokines and time would be required for their synthesis and activation of pro-cytokine molecules following stimulation and prior to release.¹⁷

Type-2 diabetes displays a unique bi-directional relationship with chronic periodontitis, namely that chronic periodontitis is a risk factor for type-2 diabetes and vice-versa,¹⁸ with periodontal treatment reliably shown to improve glycaemic control.¹⁹ Peripheral blood neutrophils isolated from diabetes patients have recently been shown to release greater amounts of IL-8, IL-1 β and TNF α when cultured for 18 hr, in the presence and absence of LPS, than neutrophils isolated from healthy controls.⁵ To date, there are no studies investigating cytokine release, in the presence or absence of recognised periodontal pathogens, within an extended (18 hr) culture period, from neutrophils isolated from patients with chronic periodontitis. Furthermore, there have been no studies on the effects of successful periodontal therapy on neutrophil cytokine production in periodontitis.

Here we determined neutrophil cytokine release following 18 hr culture in the absence of and following stimulation with *E. coli* LPS, opsonised *S. aureus* and the periodontal pathogens, *F. nucleatum* and *P. gingivalis*. In addition, the effect of non-surgical periodontal therapy and stabilisation of periodontal disease on neutrophil cytokine release was also investigated. Given the increasing awareness of the ability of neutrophils to secrete cytokines and co-ordinate the inflammatory-immune response, we hypothesised that increased cytokine release from peripheral blood neutrophils may be involved in the pathogenesis of chronic periodontitis and have a potential role in associated systemic diseases.

MATERIALS & METHODS

Ethical approval

Ethical approval was granted by the West Midlands Research Ethics Committee (REC reference no. 10/H1208/48). National Health Service (NHS) permission was granted by the Birmingham Community Healthcare NHS Trust on behalf of the Birmingham and the Black Country Comprehensive Local Research Network (BBC CLRN) Research Management & Governance (RM&G) Consortium Office (NHS R&D reference no. R&D1398; RM&G reference no. BCHCTDent265.1398.P). The study was adopted onto the National Institute of Health Research Network Portfolio (NIHR UKCRN Study ID 10318). The study was also registered on ClinicalTrials.gov (Identifier NCT01233765). The study was classified as a clinical study and came under the Department of Health Research Governance Framework for Health and Social Care.

Volunteer recruitment

Volunteers diagnosed with chronic periodontitis (n=20) were recruited from patients referred to the Birmingham Dental Hospital for clinical evaluation and treatment (12 male and 8 female; mean age = 46 ± 8 yrs, range 37-61 yr). Chronic periodontitis was defined as the presence of at least two non-adjacent sites with probing pocket depths >4 mm, along with radiographic bone loss $\geq 30\%$ of the root length (non-first molar or incisor sites) in accordance with the consensus criteria of the European Federation of Periodontology.²⁰ Age- and gender-matched periodontally healthy control volunteers (n=20) were recruited from Staff of the Birmingham Dental Hospital & School (12 male, 8 female; mean age = 46 ± 8 yrs, range 32-62 yr). There were no significant differences in patient and control volunteer age as determined by Mann-Whitney test. Control volunteers had no evidence of attachment loss, no probing pocket depths >4 mm and whole-mouth bleeding scores $<10\%$. All volunteers were never-smokers and systemically healthy as confirmed by a detailed medical history questionnaire.

Periodontal assessment

Clinical measures included probing pocket depth and recession using a PCP-UNC-15 periodontal probe (Hu-Friedy Manufacturing Co., Chicago, IL). Bleeding on probing was

recorded in conjunction with the probing pocket depth measurements. Gingival inflammation was measured using the Löe gingival index.²¹ The presence of dental plaque was measured using the modified Quigley & Hein plaque index.²² All clinical measures were recorded on 6 sites per tooth (3 measurements on each of the buccal/labial and palatal/lingual thirds) by a single calibrated examiner at baseline and 2 months post-therapy.

Non-surgical periodontal therapy

Patient volunteers received tailored oral hygiene instruction and conventional non-surgical periodontal therapy by a single operator. This consisted of scaling and root surface debridement (RSD) of all periodontal pockets >4 mm performed under local anaesthesia on a quadrant-by-quadrant basis within a maximum of 4 weeks.

Neutrophil isolation

Peripheral blood was obtained from volunteers with chronic periodontitis and age-/gender-matched controls before (baseline; n=20) and following conventional non-surgical periodontal therapy (review; n=19). Blood was obtained between 09:00 and 10:00 am from a patient and a matched healthy control volunteer within 30 minutes of each other. Blood was collected from the antecubital fossa into Vacutainers (Greiner, Bio-One Ltd, Stonehouse, UK) containing lithium heparin (17 IU/ml) as anticoagulant. Neutrophils were isolated using a discontinuous Percoll gradient ($\delta = 1.079:1.098$), followed by erythrocyte lysis (0.83 % NH_4Cl containing 1 % KHCO_3 , 0.04 % $\text{Na}_2\text{EDTA} \cdot 2\text{H}_2\text{O}$ and 0.25 % bovine serum albumin; 20 min). Isolated cells were >99 % polymorphonuclear cells morphologically and devoid of erythrocytes and monocytes. The absence of monocytes in cells prepared using this method has been confirmed previously within our laboratory by gene expression analyses.²³ Giemsa stained cell smears²⁴ also confirmed the presence of >99 % neutrophils in the cell preparation. Neutrophil isolation was performed at room temperature within a Biological Safety cabinet (Jouan Microbiological Safety Cabinet BS 5726) using aseptic technique.

Preparation of bacterial stimuli

Fusobacterium nucleatum (Fn; ATCC 10953) and *Porphyromonas gingivalis* (Pg; ATCC 33277) were grown anaerobically at 37°C as previously described.²⁵ *Staphylococcus aureus* (NCTC 6571) was grown in air on mannitol salt agar and inoculated into tryptone soya broth. Bacteria were washed 3 times in sterile PBS and heat-treated (100 °C for 10 min) prior to dilution with sterile PBS to give a final suspension of 8.5×10^9 and 4.12×10^9 for *F. nucleatum* and *P. gingivalis* respectively, and stored at -80°C. The number of *F. nucleatum* and *P. gingivalis* in cell suspensions was determined by measuring the optical density at 600nm using conversion factors previously determined by the Forsyth Institute, Boston, USA ($OD^{1.0}_{600nm} = 1.62 \times 10^9$ for *F. nucleatum* and 1.69×10^9 for *P. gingivalis*).²⁵ The bacterial density of *S. aureus* suspensions was determined by plate colony counting. Opsonised *S. aureus* was prepared as previously described²⁶ and stored as a 1.1×10^{11} cells/ml suspension at -80°C. *Escherichia coli* serotype O26:B6 lipopolysaccharide (LPS; Sigma L5543) was supplied as a 1mg/ml, 0.2 µm filtered, aqueous solution as confirmed by the product information sheet.

Neutrophil culture

Freshly isolated neutrophils were immediately washed at room temperature in PBS prior to re-suspension in RPMI-1640 (Sigma R8758) supplemented with 0.3 g/l glutamine, 2.32 g/l HEPES, 2g/l sodium bicarbonate, 100 µg/ml streptomycin, 100 IU/ml penicillin and 10 % heat-inactivated fetal bovine serum. Neutrophils were cultured at 2.5×10^6 cells/ml (18 hr at 37°C and 5% CO₂) in the presence of LPS (5µg/ml), *F. nucleatum* (MOI 100:1), *P. gingivalis* (MOI 100:1), opsonised *S. aureus* (MOI 300:1) or additional RPMI as negative control. Neutrophil viability was determined immediately before and after 18 hr culture by trypan blue dye exclusion.

Determination of neutrophil cytokine release

Following 18 hr culture, neutrophil cell culture supernatants were collected aseptically and stored at -80°C. Commercial enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Abingdon, UK) were used to measure IL-8, IL-6, TNFα and IL-1β levels within the neutrophil culture supernatants. All samples were allowed to equilibrate to room temperature before use. Standards and samples were assayed in duplicate according

to the manufacturer's instructions. All cytokine data were calculated to the nearest whole value in pg/ml due to the reported ELISA assay sensitivities and inter-assay variation (typically >1pg/ml) as specified within the product information sheets.

Data handling and statistical analyses

Data were recorded and manipulated in Microsoft Excel and evaluated using GraphPad Prism 5 (version 5.04; GraphPad Software, La Jolla, CA, USA). Data distribution was determined using the Kolmogorov-Smirnov test. Differences in probing pocket depths, the only dataset found to be normally distributed, were determined by ANOVA followed by Tukey-Kramer multiple comparisons test. All other statistical comparisons were performed using non-parametric methods as indicated in the text and/or figures/tables. Except for probing pocket depths, all data were reported as median and interquartile range. In order to assist graphical representation of the cytokine data, "outliers" were determined (calculated as $>1.5 \times$ interquartile range)²⁷ and plotted outside the boxplot, with the most extreme values above the y-axis maximum. All cytokine concentrations, including outlying values, were included in all statistical analyses.

RESULTS

Longitudinal changes in clinical measures

The success of non-surgical periodontal therapy was confirmed by improvements in all clinical measures of the disease at the 2 month post treatment review (Table 1; $P<0.05$). At review, there were no significant differences between patient and control volunteers regarding the percentage of sites exhibiting bleeding on probing or the gingival and plaque indices. However, patient volunteers continued to demonstrate greater mean probing pocket depths and number of sites >4 mm ($P<0.01$), despite significantly reducing from their baseline pre-treatment values ($P<0.05$).

Neutrophil viability following culture

There were no significant differences in neutrophil viability following 18 hr culture between patient (mean $97.7 \pm 2.3\%$; range 94.1–100%) and control cells (mean $97.5 \pm 1.8\%$; range 93.5–100%; data not shown). However, neutrophil viability in the presence of opsonised *S. aureus* (mean $95.4 \pm 2.8\%$; range 90.9–100%) was significantly lower than in cultures containing additional RPMI or other stimuli (mean $98.9 \pm 0.4\%$; range 98.4–99.2%; $P<0.05$; Friedman/Dunn's test).

Unstimulated neutrophil cytokine release

Cytokine release from essentially unstimulated neutrophils cultured in the presence of additional RPMI (vehicle control) is shown in Table 2. At both baseline and review there were significant differences in the amounts of each cytokine detected in the 18 hr culture supernatants irrespective of whether they were patient or control cells ($P<0.0001$; Friedman test), with a clear pattern of release ($\text{IL-8} > \text{IL-6} > \text{TNF}\alpha = \text{IL-1}\beta$). However there was considerable individual variation in cytokine release as evidenced by the interquartile ranges in relation to the median. Overall, the levels of all cytokines released from patient neutrophils were higher than those from controls. This difference was not significant when comparing data for all cytokines combined (i.e. total cytokine production) or individual cytokines, except at review, when patient cells released higher amounts of IL-6 than control neutrophils ($P=0.033$; Table 2). However, this latter difference coincided

with a significant decrease in detectable IL-6 release from control cells at review ($P=0.03$).

Stimulated neutrophil cytokine release

Neutrophils demonstrated a positive cytokine response to all stimuli employed (IL-8, TNF α & IL-1 β , $P<0.0004$; IL-6, $P<0.0012$; Figures 1-4).

Initially, the IL-8, IL-6, TNF α and IL-1 β data for all stimuli combined were analysed to reflect the multiple host and plaque-associated factors capable of stimulating neutrophils. Combined stimulated cytokine levels from patient cells were consistently higher than from control cells both at baseline and review ($P\leq 0.016$; Table 3) with no significant differences between baseline and review visits for control or patient cells with the exception of a significant increase in TNF α release by patient cells at review ($P=0.007$; Table 4). In agreement with unstimulated cytokine release, there were significant differences in the amounts of each cytokine detected in the 18 hr culture supernatants of patient and control cells following stimulation ($P<0.0001$ for baseline and review; Kruskal-Wallis test) with a similar pattern of release (IL-8>IL-6>TNF α =IL-1 β).

At both baseline and review the median levels of all 4 cytokines released were highest from patient cells irrespective of which stimulus was used (Figures 1-4). When analysing the data for individual stimuli, several therapy-/stimulus-related differences between cytokine release from patient and control cells were detected (Figures 1-4 & summarised in Table 4). Patient neutrophils released greater amounts of IL-8 and TNF α than controls in the presence of the periodontopathogen *F. nucleatum* at baseline ($P\leq 0.05$), with no significant differences at post-treatment review. However, this apparent therapy-related change was not reflected by a significant reduction in cytokine production by patient cells post-therapy. By contrast, heightened Fc γ R-stimulated neutrophil IL-8, TNF- α and IL-1 β release was a consistent feature of periodontitis neutrophils at both baseline ($P<0.05$) and review ($P<0.023$). Furthermore, greater release of IL-8 and IL-1 β by patient cells was also a consistent feature after stimulation with *P. gingivalis* (baseline, $P<0.032$; review, $P<0.036$), as was production of IL-8 in response to *E. coli* LPS (baseline, $P=0.038$; review, $P=0.015$).

Release of IL-8, IL-6 and IL-1 β by patient cells was unaffected by therapy. However, TNF α release by patient cells in response to opsonised *S. aureus* ($P=0.015$)

and *P. gingivalis* ($P=0.035$) was significantly higher at the post therapy review, as was TNF α production when combining the data for all stimuli ($P=0.007$; Table 4).

DISCUSSION

The data from this study demonstrate, for the first time, that peripheral blood neutrophils from patients with chronic periodontitis release greater amounts of cytokines (IL-8, IL-6, TNF α and IL-1 β) compared to those from healthy individuals and exhibit a hyper-reactive phenotype in terms of cytokine production in response to a variety of stimuli, including the periodontitis-associated periodontal bacteria, *P. gingivalis* and *F. nucleatum*. Furthermore, this is the first longitudinal intervention study analysing the impact of therapeutic reductions in periodontal inflammation on the ability of peripheral blood neutrophils to generate cytokines in the presence and absence of periodontally relevant stimuli. In most instances, the observed cytokine hyper-reactivity of patient neutrophils and their ability to release cytokines was not altered by successful non-surgical therapy. Together, these novel data are consistent with current literature highlighting a dysregulated neutrophil phenotype in chronic periodontitis pathogenesis and are significant because cytokines regulate many different aspects of the inflammatory-immune response known to be altered in periodontitis²⁸ including neutrophil reactive oxygen species (ROS) generation,^{29, 30} extracellular trap (NET) release³¹ and directional chemotactic accuracy.³²

Although median levels of unstimulated cytokine release were highest for patient cells, the difference, compared to control cell levels, was not significant for either the combined or individual cytokine data, except for IL-6 at review. This latter result was due to a significant decrease in control neutrophil IL-6 release at review compared to baseline, despite no known intervention between the sampling visits. Thus, our 18 hour culture data do not provide evidence that unstimulated peripheral blood neutrophils from periodontitis patients are hyperactive in terms of baseline, unstimulated cytokine release and agree with two reports using shorter (1-5h) culture times.^{13, 14} By contrast, the reported 4-6 times lower unstimulated release of IL-8 from patient cells compared to control neutrophils, where none of the cells responded to stimuli including *E. coli* LPS and zymosan A¹⁵, is not supported. However, further studies on larger numbers are required to determine whether the generally higher median release of cytokines by patient cells reported here would become statistically significant. This is of potential importance because even small differences in “baseline”, unstimulated cytokine release may be

biologically important in the pathogenesis of periodontitis, given the large numbers of systemic and locally recruited neutrophils within the periodontium and the chronic nature of the disease.

Although cytokine hyperactivity (increased cytokine release in the absence of stimulation) was not statistically significant, greater stimulated IL-8, IL-6, TNF α and IL-1 β release from patient compared to control neutrophils was a consistent feature when comparing data for all stimuli combined demonstrating that patient cells are hyper-reactive in terms of cytokine production. While these analyses of cytokine responses to multiple stimuli suggest that patient neutrophils will be hyper-reactive to the many host and plaque-associated factors known to be simultaneously present within periodontal tissues and blood,³³ it is important to remember that our data are based on summation of cytokine release stimulated by individual stimuli rather than responses to the combined stimuli.

The pattern of stimulated cytokine responses by neutrophils from patient cells varied according to the individual stimulus and cytokine investigated. Untreated patient neutrophils released significantly greater amounts of IL-8 in response to all tested stimuli compared to control cells. By contrast, there were no significant differences in stimulated IL-6 release between patient and control cells for any of the stimuli. TNF α and IL-1 β release by patient cells showed an intermediate response profile showing hyper-reactivity to opsonised *S. aureus* (TNF α & IL-1 β), *F. nucleatum* (TNF α) and *P. gingivalis* (IL-1 β).

The Fc γ R-stimulated IL-8, TNF α and IL-1 β hyper-reactivity presented in this study contrasts with the lack of significant differences between periodontitis and control neutrophils previously reported (Fredriksson *et al.* 2002). However, Fredriksson *et al.* utilised a 5 hr culture time and detected only low levels of Fc γ R-stimulated IL-8 (range 16-64 pg/ml) and TNF α (range 13-248 pg/ml). By comparison, high levels of cytokine were detected in this study (stimulated ranges: IL-8, 496-118466 pg/ml; TNF α , 2-8326 pg/ml) using an 18 hr culture period, a time known to correspond to that required for the majority of stimulated neutrophil IL-8, IL-6, TNF α and IL-1 β to be released (16-18 hr).³⁴

³⁵ Similarly, the significantly greater *E. coli* LPS and *P. gingivalis*-stimulated IL-8 release from patient compared to control neutrophils presented here contrasts with a study reporting lower *E. coli* LPS and *P. gingivalis*-stimulated IL-8 release from periodontitis neutrophils.¹⁵ However, this latter study only used a 1 hr culture time and failed to

demonstrate stimulation of control neutrophils, which produced extremely high levels of IL-8 (~800ng) in the absence of stimulation.

This is the first known study to investigate the effect of successful periodontal treatment on peripheral blood neutrophil cytokine release. There were no detectable changes in IL-8, IL-6 or IL-1 β production by patient neutrophils at the post-therapy review, indicating that any neutrophil cytokine hyperactivity/-reactivity detected was constitutive rather than being secondary to the inflammatory process. Indeed, significant differences between patient and control cell release of IL-8, IL-6 and IL-1 β detected pre-therapy were also demonstrated post-therapy, except for *F. nucleatum*-stimulated IL-8. This finding contrasts with data on Fc γ R-stimulated neutrophil ROS hyper-reactivity in periodontitis, which is not detectable following treatment.³⁰ In contrast to IL-8, IL-6 or IL-1 β , a therapy-related increase in TNF α release by patient cells was detected when analysing responses to opsonised *S. aureus*, *P. gingivalis* and all stimuli combined. Although this change had no positive effect on TNF α hyper-reactivity detected at pre-therapy baseline, it is difficult to explain why reducing the inflammatory burden to the body, by reducing the periodontal bacterial load and inflammation, should apparently increase stimulated TNF α production by patient neutrophils.

In terms of periodontitis, an important and novel finding was the consistent IL-8 and IL-1 β hyper-reactivity of patient cells to *P. gingivalis*, a bacterium strongly associated with chronic periodontitis.³⁶ *Porphyromonas gingivalis* LPS is structurally distinct from other sources of LPS,³⁷ induces cytokine production via different signalling mechanisms³⁸ and is heterogenous, with some *P. gingivalis* LPS molecules binding to TLR-2, others to TLR-4 and, possibly, also to receptor antagonists.^{39, 40} Taken together, a constitutive defect in TLR receptor or downstream signalling relating to IL-8 and IL-1 β release may explain the persistent hyper-reactive *P. gingivalis*-stimulated cytokine release from patient compared to control neutrophils detected in this study.

In contrast to the response to *P. gingivalis*, neutrophil hyper-reactivity to *F. nucleatum*, a bacterium known to be important in plaque associated with periodontitis,^{36, 41} was detected before treatment (IL-8 & TNF α) but could not be demonstrated post-therapy. As patient levels of both cytokines were not lowered after treatment, this apparent loss of hyper-reactivity cannot be attributed to reduced periodontal bacterial load

and inflammation. Further studies are obviously required to determine the significance of these observations.

Dysregulated neutrophil cytokine release, namely cytokine hyper-reactivity to periodontal pathogens and FcγR activation, could have a number of different consequences on the inflammatory-immune response in relation to the pathogenesis of chronic periodontitis. Greater neutrophil IL-8, IL-6, and TNFα release may result in neutrophil priming for greater ROS release.^{42, 43} Increased extracellular ROS release may then result in collateral host tissue damage as a result of osteoclast activation causing bone resorption⁴⁴ in addition to degradation of type I collagen of the periodontal ligament.⁴⁵ Neutrophil ROS and IL-8 release will also result in NET formation^{46, 47} which, if excessive, may result in the generation of autoantibodies⁴⁸ along with impairing the inflammatory-immune response by sequestering local cytokine dissemination.⁴⁹ Heightened release of IL-8, IL-6, TNFα and IL-1β by neutrophils could also trigger neutrophil antimicrobial enzyme and granule protein release with the potential to cause destruction of adjacent periodontal connective tissue.⁵⁰

In addition to the above, there are a variety of indirect effects of dysregulated neutrophil cytokine release that could impact on the pathogenesis of chronic periodontitis. For example, neutrophil IL-8 release is likely to affect concurrent neutrophil chemotaxis and recruitment within the periodontal tissues.⁵¹ Our group have demonstrated that peripheral blood neutrophils from periodontitis patients display impaired directional chemotactic accuracy³² and, in this patient and control cohort, we have shown a moderate positive correlation between neutrophil IL-8 release and chemotactic index towards fMLP, suggesting that neutrophil IL-8 release may assist with neutrophil chemotaxis towards bacterial-derived chemo-attractants (Ling MR, Chapple IL, Roberts HM., Matthews JB, unpublished observations). In addition, any adaptive immune response will be heightened by IL-8, IL-6 and TNFα resulting in T-cell activation which is also directly influenced by IL-6.⁵² The generation of antibodies and bacterial opsonisation will result in FcγR-stimulated neutrophil activation thereby further exacerbating the inflammatory-immune response in relation to the persistent FcγR-stimulated IL-8, IL-6, IL-1β and TNFα release and FcγR-stimulated neutrophil ROS hyper-reactivity in chronic periodontitis.³⁰

Overall, the data presented in this study demonstrate that neutrophils from untreated periodontitis patients are hyper-reactive to a variety of disease-associated stimuli with regards to IL-8, IL-6, TNF α and IL-1 β release compared to cells from healthy control individuals. Furthermore, production of cytokines by patient cells was not reduced after successful non-surgical periodontal therapy and, except for responses to *F. nucleatum*, cytokine hyper-reactivity detected pre-therapy was shown to be retained. These data suggest that neutrophil cytokine hyper-reactivity is not secondary to the inflammatory reaction within the periodontal tissues during periodontal disease but is the result of constitutive differences in neutrophils isolated from controls and periodontitis patients. Such a difference in neutrophil reactivity could modulate both local and systemic inflammatory-immune responses and influence the risk and severity of periodontitis, as well as periodontitis-associated systemic inflammatory disease.

Funding Acknowledgements

This work was supported by the Oral & Dental Research Trust [grant number 14945].

Conflict of Interest Statement

The Authors declare that there is no conflict of interest.

REFERENCES

1. Kassebaum NJ, Bernabe E, Dahiya M, et al. Global burden of severe periodontitis in 1990-2010: a systematic review and meta-regression. *Journal of dental research* 2014; 93: 1045-53.
2. Van Dyke TE. The management of inflammation in periodontal disease. *Journal of periodontology* 2008; 79: 1601-8.
3. Page RC and Kornman KS. The pathogenesis of human periodontitis: an introduction. *Periodontology 2000* 1997; 14: 9-11.
4. Chapple IL and Matthews JB. The role of reactive oxygen and antioxidant species in periodontal tissue destruction. *Periodontology 2000* 2007; 43: 160-232.
5. Hatanaka E, Monteagudo PT, Marrocos MS et al. Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes. *Clinical and experimental immunology* 2006; 146: 443-7.
6. Yasunari K, Watanabe T and Nakamura M. Reactive oxygen species formation by polymorphonuclear cells and mononuclear cells as a risk factor of cardiovascular diseases. *Current pharmaceutical biotechnology* 2006; 7: 73-80.
7. Stow JL, Low PC, Offenhauser C et al. Cytokine secretion in macrophages and other cells: pathways and mediators. *Immunobiology* 2009; 214: 601-12.
8. Altstaedt J, Kirchner H and Rink L. Cytokine production of neutrophils is limited to interleukin-8. *Immunology* 1996; 89: 563-8.
9. Cassatella MA, Gasperini S and Russo MP. Cytokine expression and release by neutrophils. *Annals of the New York Academy of Sciences* 1997; 832: 233-42.
10. Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. *Advances in immunology* 1999; 73: 369-509.
11. Kasama T, Miwa Y, Isozaki T, et al. Neutrophil-derived cytokines: potential therapeutic targets in inflammation. *Current drug targets Inflammation and allergy* 2005; 4: 273-9.
12. Kumar V and Sharma A. Neutrophils: Cinderella of innate immune system. *International immunopharmacology* 2010; 10: 1325-34.

13. Galbraith GM, Hagan C, Steed RB, et al. Cytokine production by oral and peripheral blood neutrophils in adult periodontitis. *Journal of periodontology* 1997; 68: 832-8.
14. Fredriksson M, Bergstrom K and Asman B. IL-8 and TNF-alpha from peripheral neutrophils and acute-phase proteins in periodontitis. *Journal of clinical periodontology* 2002; 29: 123-8.
15. Restaino CG, Chaparro A, Valenzuela MA, et al. Stimulatory response of neutrophils from periodontitis patients with periodontal pathogens. *Oral diseases* 2007; 13: 474-81.
16. Futosi K, Fodor S and Mocsai A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. *International immunopharmacology* 2013; 17: 638-50.
17. Lloyd AR and Oppenheim JJ. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. *Immunology today* 1992; 13: 169-72.
18. Taylor GW. Bidirectional interrelationships between diabetes and periodontal diseases: an epidemiologic perspective. *Ann Periodontol* 2001; 6: 99-112.
19. Chapple I and Genco R. Diabetes and periodontal disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *Journal of periodontology* 2013; 84: S106-S12.
20. Tonetti MS, Claffey N and European Workshop in Periodontology group C. Advances in the progression of periodontitis and proposal of definitions of a periodontitis case and disease progression for use in risk factor research. Group C consensus report of the 5th European Workshop in Periodontology. *Journal of clinical periodontology* 2005; 32 Suppl 6: 210-3.
21. Loe H. The Gingival Index, the Plaque Index and the Retention Index Systems. *Journal of periodontology* 1967; 38: Suppl:610-6.
22. Quigley GA and Hein JW. Comparative cleansing efficiency of manual and power brushing. *Journal of the American Dental Association* 1962; 65: 26-9.
23. Wright HJ, Matthews JB, Chapple IL, et al. Periodontitis associates with a type 1 IFN signature in peripheral blood neutrophils. *J Immunol* 2008; 181: 5775-84.

24. Barcia JJ. The Giemsa stain: its history and applications. *International journal of surgical pathology* 2007; 15: 292-6.
25. Roberts A, Matthews JB, Socransky SS, et al. Stress and the periodontal diseases: effects of catecholamines on the growth of periodontal bacteria in vitro. *Oral microbiology and immunology* 2002; 17: 296-303.
26. Bergstrom K and Asman B. Luminol enhanced Fc-receptor dependent chemiluminescence from peripheral PMN cells. A methodological study. *Scandinavian journal of clinical and laboratory investigation* 1993; 53: 171-7.
27. Tukey J. Exploratory data analysis. *Addison-Wesley Reading: MA*. 1977.
28. Preshaw PM and Taylor JJ. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? *Journal of clinical periodontology* 2011; 38 Suppl 11: 60-84.
29. Matthews JB, Wright HJ, Roberts A, et al. Hyperactivity and reactivity of peripheral blood neutrophils in chronic periodontitis. *Clinical and experimental immunology* 2007; 147: 255-64.
30. Matthews JB, Wright HJ, Roberts A, et al. Neutrophil hyper-responsiveness in periodontitis. *Journal of dental research* 2007; 86: 718-22.
31. Cooper PR, Palmer LJ and Chapple IL. Neutrophil extracellular traps as a new paradigm in innate immunity: friend or foe? *Periodontology 2000* 2013; 63: 165-97.
32. Roberts HM, Ling MR, Insall R, et al. Impaired neutrophil directional chemotactic accuracy in chronic periodontitis patients. *Journal of clinical periodontology* 2015; 42: 1-11.
33. Scott DA and Krauss J. Neutrophils in periodontal inflammation. *Frontiers of oral biology* 2012; 15: 56-83.
34. Retini C, Vecchiarelli A, Monari C, et al. Capsular polysaccharide of *Cryptococcus neoformans* induces proinflammatory cytokine release by human neutrophils. *Infection and immunity* 1996; 64: 2897-903.
35. Hattar K, Grandel U, Moeller A, et al. Lipoteichoic acid (LTA) from *Staphylococcus aureus* stimulates human neutrophil cytokine release by a CD14-dependent, Toll-like-receptor-independent mechanism: Autocrine role of tumor necrosis factor-[alpha] in mediating LTA-induced interleukin-8 generation. *Critical care medicine* 2006; 34: 835-41.

36. Socransky SS, Haffajee AD, Cugini MA, et al. Microbial complexes in subgingival plaque. *Journal of clinical periodontology* 1998; 25: 134-44.
37. Ogawa T. Chemical structure of lipid A from Porphyromonas (Bacteroides) gingivalis lipopolysaccharide. *FEBS letters* 1993; 332: 197-201.
38. Diya Z, Lili C, Shenglai L, et al. Lipopolysaccharide (LPS) of Porphyromonas gingivalis induces IL-1beta, TNF-alpha and IL-6 production by THP-1 cells in a way different from that of Escherichia coli LPS. *Innate immunity* 2008; 14: 99-107.
39. Hajishengallis G, Martin M, Schifferle RE et al. Counteracting interactions between lipopolysaccharide molecules with differential activation of toll-like receptors. *Infection and immunity* 2002; 70: 6658-64.
40. Darveau RP, Pham TT, Lemley K, et al. Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. *Infection and immunity* 2004; 72: 5041-51.
41. Kolenbrander PE, Parrish KD, Andersen RN et al. Intergeneric coaggregation of oral Treponema spp. with Fusobacterium spp. and intrageneric coaggregation among Fusobacterium spp. *Infection and immunity* 1995; 63: 4584-8.
42. Guichard C, Pedruzzi E, Dewas C, et al. Interleukin-8-induced priming of neutrophil oxidative burst requires sequential recruitment of NADPH oxidase components into lipid rafts. *The Journal of biological chemistry* 2005; 280: 37021-32.
43. Chen LW, Huang HL, Lee IT, et al. Thermal injury-induced priming effect of neutrophil is TNF-alpha and P38 dependent. *Shock* 2006; 26: 69-76.
44. Lee NK, Choi YG, Baik JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. *Blood* 2005; 106: 852-9.
45. Henrotin YE, Bruckner P and Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 2003; 11: 747-55.
46. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. *Science* 2004; 303: 1532-5.
47. Palmer LJ, Cooper PR, Ling MR, et al. Hypochlorous acid regulates neutrophil extracellular trap release in humans. *Clinical and experimental immunology* 2012; 167: 261-8.

48. de Pablo P, Dietrich T, Chapple IL, et al. The autoantibody repertoire in periodontitis: a role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? *Annals of the rheumatic diseases* 2014; 73: 580-6.
49. Bank U and Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. *Journal of leukocyte biology* 2001; 69: 197-206.
50. Lacy P. Mechanisms of degranulation in neutrophils. *Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology* 2006; 2: 98-108.
51. Hammond ME, Lapointe GR, Feucht PH, et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. *J Immunol* 1995; 155: 1428-33.
52. Maeda K, Mehta H, Drevets DA, et al. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. *Blood* 2010; 115: 4699-706.

TABLE LEGENDS

Table 1.

Clinical measures of chronic periodontitis patients before (baseline; n=20) and 2 months after (review; n=19) non-surgical periodontal therapy and matched healthy controls (n=20). One patient (no. 13) elected to discontinue participation in the study during the treatment phase of the study. Probing pocket depths [mean \pm SD] were compared by one-way ANOVA followed by Tukey-Kramer multiple comparisons test. All other comparisons [median (IQ range)] were performed using Kruskal-Wallis test followed by Dunn's multiple comparisons test.

* comparison with controls # comparison with chronic periodontitis before treatment

Table 2.

Unstimulated IL-8, IL-6, TNF α and IL-1 β release (pg/ml) from patient (n=19) and control (n=19) neutrophils at baseline and review. Data presented as median (interquartile range) pg/ml. For both patient and control cells at baseline and review, levels of IL-8 were higher than IL-6 ($P<0.05$), which were higher than TNF α and IL-1 β ($P<0.05$). There were no differences in levels of TNF α and IL-1 β released (Dunn's Test). * The only significant difference in unstimulated cytokine levels between patient & control cells was for IL-6 at review ($P=0.033$; Bonferroni corrected, 1-tailed Mann-Whitney).

Table 3.

Stimulated IL-8, IL-6, TNF α and IL-1 β release (pg/ml) from patient (n=19) and control (n=19) neutrophils at baseline and review in the presence of *E. coli* LPS (5 μ g/ml), *F. nucleatum* (MOI 100:1), IgG-opsonised *S. aureus* (MOI 300:1) and *P. gingivalis* (MOI 100:1). Individual cytokine data presented as median (interquartile range) pg/ml for all stimuli combined (baseline, n=75; review, n=76). For both patient and control cells at baseline and review, levels of IL-8 were higher than IL-6 ($P<0.001$), which were higher than TNF α and IL-1 β ($P<0.001$). There were no differences in levels of TNF α and IL-1 β released (Dunn's Test). # Bonferroni corrected, 1-tailed Mann-Whitney test. * $P=0.007$, Bonferroni corrected, 2-tailed Wilcoxon test.

Table 4.

Differences in cytokine release between patient and control neutrophils at baseline and review in response to individual (n=19; n=18 for opsonised *S. aureus* at baseline) and combined stimuli (n=75 at baseline and n=76 at review) (↑, patient>control; ↔, patient = control; Bonferroni corrected, 1-tailed Mann-Whitney) and change in cytokine release post-therapy (↑, increase; ↓, decrease; ↔, no change at review; Bonferroni corrected 2-tailed Wilcoxon).

Clinical measure	Chronic periodontitis patients		Controls (n=20)
	Baseline (n=20)	Review (n=19)	
Probing pocket depth (mm; mean \pm SD)	3.0 \pm 0.8 ($P<0.001$)*	2.1 \pm 0.5 ($P<0.001$)#	1.5 \pm 0.4
Number of probing pocket depths >4 mm (median; range)	27 (5-91) ($P<0.001$)*	7 (0-52) ($P<0.05$)#	0 (0-4)
Percentage of sites bleeding on probing (median; range)	43 (16-87) ($P<0.001$)*	14 (3-35) ($P<0.001$)#	2 (0-39)
Gingival index (median; range)	2 (1-3) ($P<0.001$)*	1 (0-1) ($P<0.001$)#	1 (0-1)
Plaque index (median; range)	2 (1-3) ($P<0.001$)*	1 (0-2) ($P<0.001$)#	1 (0-2)

Table 1. Clinical measures of chronic periodontitis patients before (baseline; n=20) and 2 months after (review; n=19) non-surgical periodontal therapy and matched healthy controls (n=20). One patient (no. 13) elected to discontinue participation in the study during the treatment phase of the study. Probing pocket depths [mean \pm SD] were compared by one-way ANOVA followed by Tukey-Kramer multiple comparisons test. All other comparisons [median (IQ range)] were performed using Kruskal-Wallis test followed by Dunn's multiple comparisons test.

* comparison with controls # comparison with chronic periodontitis before treatment

Cytokine	Patient		Control	
	Baseline	Review	Baseline	Review
IL-8	479 (267-1073)	518 (295-1,988)	300 (117-642)	260 (177-1,288)
IL-6	82 (37-107)	36* (18-107)	45 (23-141)	16* (11-53)
TNF α	8 (4-12)	8 (3-14)	6 (1-10)	6 (4-12)
IL-1 β	8 (4-15)	5 (2-11)	3 (2-18)	3 (2-6)

Table 2. Unstimulated IL-8, IL-6, TNF α and IL-1 β release (pg/ml) from patient (n=19) and control (n=19) neutrophils at baseline and review. Data presented as median (interquartile range) pg/ml. For both patient and control cells at baseline and review, levels of IL-8 were higher than IL-6 ($P<0.05$), which were higher than TNF α and IL-1 β ($P<0.05$). There were no differences in levels of TNF α and IL-1 β released (Dunn's Test). * The only significant difference in unstimulated cytokine levels between patient & control cells was for IL-6 at review ($P=0.033$; Bonferroni corrected, 1-tailed Mann-Whitney).

Cytokine	Patient		Control		Comparisons [#] between patient & control cytokine levels at:	
	Baseline	Review	Baseline	Review	Baseline	Review
IL-8	18,145 (7,972-31,936)	17,467 (9,043-32,937)	7,271 (4,194-13,923)	8,117 (4,569-13,380)	$P<0.0001$	$P<0.0001$
IL-6	379 (159-785)	356 (139-900)	200 (88-474)	232 (119-374)	$P=0.004$	$P=0.01$
TNF α	97* (60-224)	158* (60-346)	69 (32-127)	83 (54-155)	$P=0.016$	$P=0.008$
IL-1 β	72 (31-139)	73 (26-161)	34 (21-92)	33 (18-74)	$P=0.002$	$P=0.002$

Table 3. Stimulated IL-8, IL-6, TNF α and IL-1 β release (pg/ml) from patient (n=19) and control (n=19) neutrophils at baseline and review in the presence of *E. coli* LPS (5 μ g/ml), *F. nucleatum* (MOI 100:1), IgG-opsonised *S. aureus* (MOI 300:1) and *P. gingivalis* (MOI 100:1). Individual cytokine data presented as median (interquartile range) pg/ml for all stimuli combined (baseline, n=75; review, n=76). For both patient and control cells at baseline and review, levels of IL-8 were higher than IL-6 ($P<0.001$), which were higher than TNF α and IL-1 β ($P<0.001$). There were no differences in levels of TNF α and IL-1 β released (Dunn's Test). [#] Bonferroni corrected, 1-tailed Mann-Whitney test. * $P=0.007$, Bonferroni corrected, 2-tailed Wilcoxon test.

Cytokine	Stimulus	Difference in cytokine release between patient & control cells		Change in cytokine release between baseline & review	
		Pre-therapy Baseline	Post-therapy Review	Patient	Control
IL-8	None (RPMI)	↔	↔	↔	↔
	<i>E. coli</i> LPS	↑ (<i>P</i> =0.038)	↑ (<i>P</i> =0.015)	↔	↔
	<i>F. nucleatum</i>	↑ (<i>P</i> =0.025)	↔	↔	↔
	ops <i>S. aureus</i>	↑ (<i>P</i> =0.0002)	↑ (<i>P</i> <0.0001)	↔	↔
	<i>P. gingivalis</i>	↑ (<i>P</i> =0.029)	↑ (<i>P</i> =0.009)	↔	↔
	All stimuli	↑ (<i>P</i> <0.0001)	↑ (<i>P</i> <0.0001)	↔	↔
IL-6	None (RPMI)	↔	↑ (<i>P</i> =0.033)	↔	↓ (<i>P</i> =0.03)
	<i>E. coli</i> LPS	↔	↔	↔	↔
	<i>F. nucleatum</i>	↔	↔	↔	↔
	ops <i>S. aureus</i>	↔	↑ (<i>P</i> =0.023)	↔	↔
	<i>P. gingivalis</i>	↔	↔	↔	↔
	All stimuli	↑ (<i>P</i> =0.004)	↑ (<i>P</i> =0.01)	↔	↔
TNFα	None (RPMI)	↔	↔	↔	↔
	<i>E. coli</i> LPS	↔	↔	↔	↔
	<i>F. nucleatum</i>	↑ (<i>P</i> =0.05)	↔	↔	↔
	ops <i>S. aureus</i>	↑ (<i>P</i> =0.016)	↑ (<i>P</i> =0.009)	↑ (<i>P</i> =0.016)	↔
	<i>P. gingivalis</i>	↔	↔	↑ (<i>P</i> =0.035)	↔
	All stimuli	↑ (<i>P</i> =0.016)	↑ (<i>P</i> =0.008)	↑ (<i>P</i> =0.007)	↔
IL-1β	None (RPMI)	↔	↔	↔	↔
	<i>E. coli</i> LPS	↔	↔	↔	↔
	<i>F. nucleatum</i>	↔	↔	↔	↔
	ops <i>S. aureus</i>	↑ (<i>P</i> =0.046)	↑ (<i>P</i> =0.007)	↔	↔
	<i>P. gingivalis</i>	↑ (<i>P</i> =0.032)	↑ (<i>P</i> =0.036)	↔	↔
	All stimuli	↑ (<i>P</i> =0.002)	↑ (<i>P</i> =0.002)	↔	↔

Table 4. Differences in cytokine release between patient and control neutrophils at baseline and review in response to individual (n=19; n=18 for opsonised *S. aureus* at baseline) and combined stimuli (n=75 at baseline and n=76 at review) (↑, patient>control; ↔, patient = control; Bonferroni corrected, 1-tailed Mann-Whitney) and change in cytokine release post-therapy (↑, increase; ↓ decrease; ↔, no change at review; Bonferroni corrected 2-tailed Wilcoxon).

FIGURE LEGENDS

Figure 1.

Stimulated IL-8 production by neutrophils at baseline, pre-treatment (n=19; n=18 for opsonised *S. aureus*) and review, post-treatment (n=19). Box and whisker plots showing median, interquartile range, maximum and minimum. Outliers (values $>1.5 \times \text{IQR}$) are shown as open circles (\circ) or, if above the y-axis maximum, solid circles (\bullet). P-values calculated using Bonferroni corrected 1-tailed Mann-Whitney test. Stimulated levels of IL-8 were significantly greater than those for RPMI control for all stimuli, at baseline and review, for both patient and control groups ($P < 0.0004$; Bonferroni corrected, 1-tailed Wilcoxon test).

Figure 2.

Stimulated IL-6 production by neutrophils at baseline, pre-treatment (n=19; n=18 for opsonised *S. aureus*) and review, post-treatment (n=19). Box and whisker plots showing median, interquartile range, maximum and minimum. Outliers (values $>1.5 \times \text{IQR}$) are shown as open circles (\circ) or, if above the y-axis maximum, solid circles (\bullet). P-values calculated using Bonferroni corrected, 1-tailed Mann-Whitney test. Stimulated levels of IL-6 were significantly greater than those for RPMI control for all stimuli, at baseline and review, for both patient and control groups ($P < 0.0012$; Bonferroni corrected, 1-tailed Wilcoxon test).

Figure 3.

Stimulated TNF α production by neutrophils at baseline, pre-treatment (n=19; n=18 for opsonised *S. aureus*) and review, post-treatment (n=19). Box and whisker plots showing median, interquartile range, maximum and minimum. Outliers (values $>1.5 \times \text{IQR}$) are shown as open circles (\circ) or, if above the y-axis maximum, solid circles (\bullet). P-values calculated using Bonferroni corrected, 1-tailed Mann-Whitney test. Stimulated levels of TNF α were significantly greater than those for RPMI control for all stimuli, at baseline and review, for both patient and control groups ($P < 0.0004$; Bonferroni corrected, 1-tailed Wilcoxon test).

Figure 4.

Stimulated IL-1 β production by neutrophils at baseline, pre-treatment (n=19; n=18 for opsonised *S. aureus*) and review, post-treatment (n=19). Box and whisker plots showing median, interquartile range, maximum and minimum. Outliers (values >1.5xIQR) are shown as open circles (\circ) or, if above the y-axis maximum, solid circles (\bullet). *P*-values calculated using Bonferroni corrected, 1-tailed Mann-Whitney test. Stimulated levels of IL-1 β were significantly greater than those for RPMI control for all stimuli, at baseline and review, for both patient and control groups ($P<0.0004$; Bonferroni corrected, 1-tailed Wilcoxon test).




Figure 1. Stimulated IL-8 production by neutrophils at baseline, pre-treatment (n=19; n=18 for opsonised *S. aureus*) and review, post-treatment (n=19). Box and whisker plots showing median, interquartile range, maximum and minimum. Outliers (values $>1.5 \times \text{IQR}$) are shown as open circles (\circ) or, if above the y-axis maximum, solid circles (\bullet). P -values calculated using Bonferroni corrected 1-tailed Mann-Whitney test. Stimulated levels of IL-8 were significantly greater than those for RPMI control for all stimuli, at baseline and review, for both patient and control groups ($P<0.0004$; Bonferroni corrected, 1-tailed Wilcoxon test).




Figure 2. Stimulated IL-6 production by neutrophils at baseline, pre-treatment (n=19; n=18 for opsonised *S. aureus*) and review, post-treatment (n=19). Box and whisker plots showing median, interquartile range, maximum and minimum. Outliers (values >1.5xIQR) are shown as open circles (○) or, if above the y-axis maximum, solid circles (●). *P*-values calculated using Bonferroni corrected, 1-tailed Mann-Whitney test. Stimulated levels of IL-6 were significantly greater than those for RPMI control for all stimuli, at baseline and review, for both patient and control groups ($P < 0.0012$; Bonferroni corrected, 1-tailed Wilcoxon test).




Figure 3. Stimulated TNFα production by neutrophils at baseline, pre-treatment (n=19; n=18 for opsonised *S. aureus*) and review, post-treatment (n=19). Box and whisker plots showing median, interquartile range, maximum and minimum. Outliers (values >1.5xIQR) are shown as open circles (○) or, if above the y-axis maximum, solid circles (●). *P*-values calculated using Bonferroni corrected, 1-tailed Mann-Whitney test. Stimulated levels of TNFα were significantly greater than those for RPMI control for all stimuli, at baseline and review, for both patient and control groups ($P<0.0004$; Bonferroni corrected, 1-tailed Wilcoxon test).




Figure 4. Stimulated IL-1 β production by neutrophils at baseline, pre-treatment (n=19; n=18 for opsonised *S. aureus*) and review, post-treatment (n=19). Box and whisker plots showing median, interquartile range, maximum and minimum. Outliers (values >1.5xIQR) are shown as open circles (○) or, if above the y-axis maximum, solid circles (●). *P*-values calculated using Bonferroni corrected, 1-tailed Mann-Whitney test. Stimulated levels of IL-1 β were significantly greater than those for RPMI control for all stimuli, at baseline and review, for both patient and control groups ($P<0.0004$; Bonferroni corrected, 1-tailed Wilcoxon test).